T.P.21
Elisa Masat(Inserm), Federico Mingozzi(Spark Therapeutics (United States)), Damien Amelin(Inserm), K. Laloui(Sorbonne Université), P. Véron(Genethon (France)), P. Laforêt(Sorbonne Université), Olivier Benvéniste(Inserm)
Cited by 0
Related Papers
Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles
|The Journal of Immunology|2001|1.5k
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
|Journal of Clinical Investigation|2013|232
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207